Haleon (HLN) Share Price, News & Analysis

Company Overview

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also offers various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Otrivine, Theraflu, and Flonase brands for respiratory issues; anti-inflammatory and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. Haleon plc was founded in 1715 and is headquartered in Weybridge, the United Kingdom.

Key Stats

• Today's Range: 376.90 to 382
• 50-Day Range: 356.70 to 384.80
• 52-Week Range: 308.37 to 400.65
• Volume: 35.58 million shs
• Average Volume: 19.69 million shs
• Market Capitalization: £34.45 billion
• P/E Ratio: 3,175.83
• Dividend Yield: 1.57%
• Price Target: GBX 415
• Consensus Rating: Buy

Haleon Stock Analysis - MarketRank™

Haleon scored higher than 13% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Haleon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Haleon has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Haleon is 3,175.83, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 113.36.

Price to Earnings Ratio vs. Sector

The P/E ratio of Haleon is 3,175.83, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 89.82.

Price to Earnings Growth Ratio

Haleon has a PEG Ratio of 1.49. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Haleon has a P/B Ratio of 2.09. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for HLN.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Haleon pays a meaningful dividend of 1.61%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Haleon does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Haleon is 5,000.00%. Payout ratios above 75% are not desirable because they may not be sustainable.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for HLN.

News and Social Media

• Score: 1.2 / 5
• News Sentiment: N/A

News Sentiment

Haleon has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Medical companies.

Search Interest

Only 2 people have searched for HLN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Haleon to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Haleon insiders have sold 122.54% more of their company's stock than they have bought. Specifically, they have bought £124,836.64 in company stock and sold £277,805.88 in company stock.

Percentage Held by Insiders

10.74% of the stock of Haleon is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

43.88% of the stock of Haleon is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

HLN Stock Analysis - Frequently Asked Questions

How have HLN shares performed this year?

Haleon's stock was trading at GBX 321.65 on January 1st, 2024. Since then, HLN shares have increased by 18.5% and is now trading at GBX 381.10.
View the best growth stocks for 2024 here.

How do I buy shares of Haleon?

Shares of HLN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Haleon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Haleon investors own include GSK (GSK), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Cisco Systems (CSCO), Meta Platforms (META) and Unilever (ULVR).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Specialty & Generic
• Sub-Industry: Consumer Goods
• Current Symbol: LON:HLN
• CUSIP: N/A
• CIK: N/A
• Web: www.haleon.com
• Phone: 44 1932 822000
• Fax: N/A
• Employees: 25,408
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: GBX 415
• High Stock Price Target: GBX 447
• Low Stock Price Target: GBX 383
• Potential Upside/Downside: +8.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): GBX 0.12
• Trailing P/E Ratio: 3,175.83
• Forward P/E Ratio: 19.54
• P/E Growth: 1.49
• Net Income: £1.09 billion
• Net Margins: 9.66%
• Pretax Margin: N/A
• Return on Equity: 6.82%
• Return on Assets: 4.45%

Debt

• Debt-to-Equity Ratio: 54.18
• Current Ratio: 0.84
• Quick Ratio: 0.93

Sales & Book Value

• Annual Sales: £11.26 billion
• Price / Sales: 3.06
• Cash Flow: GBX 17.36 per share
• Price / Cash Flow: 21.95
• Book Value: GBX 182 per share
• Price / Book: 2.09

Miscellaneous

• Outstanding Shares: 9,040,000,000
• Free Float: N/A
• Market Cap: £34.45 billion
• Optionable: Not Optionable
• Beta: 0.19